Frontline Osimertinib Combo Prolongs Survival in Advanced EGFR+ NSCLC
Neoadjuvant osimertinib, alone or with chemotherapy, substantially improves pathological response rates in resectable EGFR‑mutated NSCLC.
The phase III NeoADAURA trial evaluated neoadjuvant osimertinib alone or with platinum‑based chemotherapy versus chemotherapy alone in 358 patients with resectable Stage II–IIIB EGFR‑mutated NSCLC. Major pathologic response rates were markedly higher with osimertinib (25–26%) than with chemotherapy alone (2%). Early event‑free survival at 12 months was 93–95% in the osimertinib arms compared with 83% for chemotherapy.
Improved major pathologic response and early event‑free survival suggest that neoadjuvant osimertinib may become a new standard of care for resectable EGFR‑mutated NSCLC, potentially enhancing long‑term outcomes and enabling more personalised perioperative treatment.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT